Loading clinical trials...

MicroRNA Markers in Head and Neck Cancers | Clinical Trials | Clareo Health

ACTIVE_NOT_RECRUITING

MicroRNA Markers in Head and Neck Cancers

NCT04305366•University of Colorado, Denver

Summary

The purpose of this study is to investigate the presence of miRNA markers in saliva, blood, FNA and tissue specimens in patients with and without head and neck cancer and evaluate whether these miRNA markers can provide prognostic or diagnostic clinical significance in the treatment of head and neck cancer patients.

Detailed Description

Micro RNA (miRNA) markers were initially discovered in 1993 and recent research has shown that they have great potential for use as both surveillance and prognostic markers in cancer treatment, as well as potential targets for cancer therapy. Recent research has identified several miRNA markers which appear to be potential markers for head and neck squamous cell carcinoma, and these have been tested in both mouse and human banked tumor samples. These investigators hypothesize that these markers may also be present in other tissues, including fine needle aspiration biopsy, blood, and saliva specimens, and will be sensitive and specific to patients with known head and neck cancer.

Eligibility

Age

18 - 100 years

Sex

ALL

Healthy Volunteers

Yes

Inclusion Criteria

•1. Subjects between the ages of 18 and 100
•2. Patients who are seen and evaluated by a provider within the adult ENT clinic at University of Colorado Hospital
•3. Patients that present with a current or past diagnosis of head and neck cancer -OR-Patients undergoing tonsillectomy or sleep surgery as standard of care (control group)

Exclusion Criteria

•1. Under the age of 18 or over the age of 100
•2. Unwilling to participate

Locations (1)

University of Colorado Cancer Center

Aurora, Colorado, United States

Key Dates

Start Date

November 16, 2012

Primary Completion Date

December 20, 2022

Completion Date

February 1, 2027

Last Updated

February 24, 2026

Enrollment

225

ACTUAL participants

Conditions

Squamous Cell Carcinoma of Head and Neck

Interventions

Tissue collection

OTHER

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

NCT06385080

Squamous Cell Carcinoma of Head and Neck

View study

RECRUITINGNA

HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers

NCT06487403

Squamous Cell Carcinoma of Head and Neck

View study

RECRUITINGPHASE1

A Study of MGC026 in Participants With Advanced Solid Tumors

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: February 24, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

MicroRNA Markers in Head and Neck Cancers

Inclusion Criteria

Exclusion Criteria

A Study of Amivantamab Alone or in Addition to Other Treatment Agents in Participants With Head and Neck Cancer

HN-BIO 02: A Phase II Randomized Study of the Effects of Delayed Elective Radiotherapy on Head and Neck MRI and Immune Response Biomarkers

A Study of MGC026 in Participants With Advanced Solid Tumors

Drug Screening Using Novel IMD in Salivary and Head and Neck Cancers

5-Azacytidine and/or Nivolumab in Resectable HPV-Associated HNSCC

Optimised Early Management of Squamous Cell Carcinoma of the Head and Neck Cancer